Biogen [BIIB] vs Eli Lilly and [LLY] Detailed Stock Comparison

Biogen Inc.

NASDAQ
Loading...

Eli Lilly and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Biogen Inc. wins in 8 metrics, Eli Lilly and Company wins in 12 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biogen Inc. Eli Lilly and Company Better
P/E Ratio (TTM) 20.96 40.09 Biogen Inc.
Price-to-Book Ratio 1.48 31.01 Biogen Inc.
Debt-to-Equity Ratio 36.47 165.31 Biogen Inc.
PEG Ratio -0.18 0.79 Eli Lilly and Company
EV/EBITDA 8.44 26.61 Biogen Inc.
Profit Margin (TTM) 13.07% 31.67% Eli Lilly and Company
Operating Margin (TTM) 19.64% 44.90% Eli Lilly and Company
EBITDA Margin (TTM) 19.64% 44.90% Eli Lilly and Company
Return on Equity 7.39% 101.16% Eli Lilly and Company
Return on Assets (TTM) 6.14% 19.42% Eli Lilly and Company
Free Cash Flow (TTM) $1.97B $5.96B Eli Lilly and Company
Dividend Yield N/A 0.60% N/A
1-Year Return 51.01% 49.80% Biogen Inc.
Price-to-Sales Ratio (TTM) 2.73 12.63 Biogen Inc.
Enterprise Value $30.41B $843.37B Eli Lilly and Company
EV/Revenue Ratio 3.08 12.94 Biogen Inc.
Gross Profit Margin (TTM) 78.26% 82.52% Eli Lilly and Company
Revenue per Share (TTM) $68 $73 Eli Lilly and Company
Earnings per Share (Diluted) $8.79 $22.94 Eli Lilly and Company
Beta (Stock Volatility) 0.16 0.50 Biogen Inc.
Short % of Float 3.37% 0.97% Eli Lilly and Company

Biogen Inc. vs Eli Lilly and Company Stock Performance Analysis

Loading Price Chart...

BIIB
LLY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biogen Inc.3.78%-2.20%0.87%0.41%4.80%6.19%
Eli Lilly and Company1.37%-0.01%9.99%4.58%1.77%-1.46%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biogen Inc.51.01%-34.71%-31.50%-32.47%107.63%310.82%
Eli Lilly and Company49.80%149.81%446.98%1,370.98%2,882.46%2,023.77%

Performance & Financial Health Analysis: Biogen Inc. vs Eli Lilly and Company

MetricBIIBLLY
Market Information
Market Cap i$27.06B$821.31B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i1,101,5032,387,476
90 Day Avg. Volume i1,198,6542,777,749
Last Close$195.96$1,078.78
52 Week Range$121.05 - $205.97$623.78 - $1,149.10
% from 52W High-4.86%-6.12%
All-Time High$480.18 (Mar 16, 2015)$1,149.10 (May 28, 2026)
% from All-Time High-59.19%-6.12%
Growth Metrics
Quarterly Revenue Growth-0.07%0.43%
Quarterly Earnings Growth-0.07%0.51%
Financial Health
Profit Margin (TTM) i0.13%0.32%
Operating Margin (TTM) i0.20%0.45%
Return on Equity (TTM) i0.07%1.01%
Debt to Equity (MRQ) i36.47165.31
Cash & Liquidity
Book Value per Share (MRQ)$124.37$29.66
Cash per Share (MRQ)$26.00$8.14
Operating Cash Flow (TTM) i$2.20B$16.81B
Levered Free Cash Flow (TTM) i$1.98B$1.95B
Dividends
Last 12-Month Dividend Yield iN/A0.60%
Last 12-Month Dividend iN/A$6.23

Valuation & Enterprise Metrics Analysis: Biogen Inc. vs Eli Lilly and Company

MetricBIIB (Apr 26, 2026)LLY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.9640.09
Forward P/E i11.5121.82
PEG Ratio i-0.180.79
Price to Sales (TTM) i2.7312.63
Price to Book (MRQ) i1.4831.01
Market Capitalization
Market Capitalization i$27.06B$821.31B
Enterprise Value i$30.41B$843.37B
Enterprise Value Metrics
Enterprise to Revenue i3.0812.94
Enterprise to EBITDA i8.4426.61
Risk & Other Metrics
Beta i0.160.50
Book Value per Share (MRQ) i$124.37$29.66

Financial Statements Comparison: Biogen Inc. vs Eli Lilly and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIIB (2025)LLY (2025)
Revenue/Sales i9.89B65.18B
Cost of Goods Sold i2.40B11.05B
COGS % of Revenue i24.3%17.0%
Gross Profit i7.49B54.13B
Gross Margin i75.7%83.0%
Research & Development i1.78B13.34B
Operating Income (EBIT) i2.47B29.70B
Operating Margin i25.0%45.6%
EBITDA i3.40B35.09B
EBITDA Margin i34.4%53.8%
Pre-Tax Income i1.56B25.73B
Pre-Tax Income % of Revenue i15.7%39.5%
Income Tax i263.60M5.09B
Income Tax % of Revenue i2.7%7.8%
Net Income (Profit) i1.29B20.64B
Profit Margin i13.1%31.7%

Balance Sheet & Liquidity Metrics

MetricBIIB (2025)LLY (2025)
Cash & Equivalents i3.01B7.27B
Total Current Assets i8.97B55.63B
Total Current Assets % of Revenue i90.7%85.3%
Total Current Liabilities i3.35B35.23B
Total Current Liabilities % of Revenue i33.9%54.0%
Long-Term Debt i6.58B40.87B
Long-Term Debt % of Revenue i66.5%62.7%
Total Shareholders Equity i18.26B26.54B
Retained Earnings i20.55B24.47B
Retained Earnings % of Revenue i207.8%37.5%
Property, Plant & Equipment i265.40M13.49B

Cash Flow Statement Comparison

MetricBIIB (2025)LLY (2025)
Operating Cash Flow i1.95B23.60B
Operating Cash Flow % of Revenue i19.8%36.2%
Capital Expenditures i-153.80M-7.84B
Free Cash Flow i1.97B5.96B
FCF Margin i19.9%9.2%
Debt Repayment i-1.75B-778.00M
Common Stock Repurchase iN/A-4.11B

Short Interest & Institutional Ownership Analysis

MetricBIIBLLY
Shares Short i3.83M7.70M
Short Ratio i3.962.73
Short % of Float i3.37%0.97%
Shares Outstanding i146.80M894.80M
Float Shares i146.28M890.99M
% Held by Insiders i0.17%0.17%
% Held by Institutions i98.82%84.77%
% Held by Public i1.01%15.06%

Dividend Analysis & Yield Comparison: Biogen Inc. vs Eli Lilly and Company

MetricBIIBLLY
Last 12-Month Dividend iN/A$6.23
Last 12-Month Dividend Yield iN/A0.60%
3-Year Avg Annual Dividend iN/A$5.44
3-Year Avg Dividend Yield iN/A0.18%
3-Year Total Dividends iN/A$16.32
Ex-Dividend DateN/AFeb 13, 2026